298 related articles for article (PubMed ID: 18783990)
1. Invariant natural killer T cells and immunotherapy of cancer.
Molling JW; Moreno M; van der Vliet HJ; van den Eertwegh AJ; Scheper RJ; von Blomberg BM; Bontkes HJ
Clin Immunol; 2008 Nov; 129(2):182-94. PubMed ID: 18783990
[TBL] [Abstract][Full Text] [Related]
2. Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity.
Molling JW; Moreno M; van der Vliet HJ; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
J Immunol Methods; 2007 Apr; 322(1-2):70-81. PubMed ID: 17343874
[TBL] [Abstract][Full Text] [Related]
3. Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis.
Mallevaey T; Fontaine J; Breuilh L; Paget C; Castro-Keller A; Vendeville C; Capron M; Leite-de-Moraes M; Trottein F; Faveeuw C
Infect Immun; 2007 May; 75(5):2171-80. PubMed ID: 17353286
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseases.
Miyake S; Yamamura T
Int Rev Immunol; 2007; 26(1-2):73-94. PubMed ID: 17454265
[TBL] [Abstract][Full Text] [Related]
5. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity.
Wilson SB; Delovitch TL
Nat Rev Immunol; 2003 Mar; 3(3):211-22. PubMed ID: 12658269
[TBL] [Abstract][Full Text] [Related]
6. The in vivo response of invariant natural killer T cells to glycolipid antigens.
Parekh VV; Lalani S; Van Kaer L
Int Rev Immunol; 2007; 26(1-2):31-48. PubMed ID: 17454263
[TBL] [Abstract][Full Text] [Related]
7. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
8. Natural killer T cell-mediated antitumor immune responses and their clinical applications.
Seino K; Motohashi S; Fujisawa T; Nakayama T; Taniguchi M
Cancer Sci; 2006 Sep; 97(9):807-12. PubMed ID: 16805854
[TBL] [Abstract][Full Text] [Related]
9. Co-inhibitory roles for glucocorticoid-induced TNF receptor in CD1d-dependent natural killer T cells.
Chen S; Ndhlovu LC; Takahashi T; Takeda K; Ikarashi Y; Kikuchi T; Murata K; Pandolfi PP; Riccardi C; Ono M; Sugamura K; Ishii N
Eur J Immunol; 2008 Aug; 38(8):2229-40. PubMed ID: 18624295
[TBL] [Abstract][Full Text] [Related]
10. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids.
Paget C; Mallevaey T; Speak AO; Torres D; Fontaine J; Sheehan KC; Capron M; Ryffel B; Faveeuw C; Leite de Moraes M; Platt F; Trottein F
Immunity; 2007 Oct; 27(4):597-609. PubMed ID: 17950005
[TBL] [Abstract][Full Text] [Related]
11. CD1d-restricted glycolipid antigens: presentation principles, recognition logic and functional consequences.
Florence WC; Bhat RK; Joyce S
Expert Rev Mol Med; 2008 Jul; 10():e20. PubMed ID: 18601810
[TBL] [Abstract][Full Text] [Related]
12. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma.
Molling JW; Langius JA; Langendijk JA; Leemans CR; Bontkes HJ; van der Vliet HJ; von Blomberg BM; Scheper RJ; van den Eertwegh AJ
J Clin Oncol; 2007 Mar; 25(7):862-8. PubMed ID: 17327607
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometry for natural killer T cells: multi-parameter methods for multifunctional cells.
Metelitsa LS
Clin Immunol; 2004 Mar; 110(3):267-76. PubMed ID: 15047204
[TBL] [Abstract][Full Text] [Related]
14. Aging is associated with a rapid decline in frequency, alterations in subset composition, and enhanced Th2 response in CD1d-restricted NKT cells from human peripheral blood.
Jing Y; Gravenstein S; Chaganty NR; Chen N; Lyerly KH; Joyce S; Deng Y
Exp Gerontol; 2007 Aug; 42(8):719-32. PubMed ID: 17368996
[TBL] [Abstract][Full Text] [Related]
15. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity.
Lynch L; O'Shea D; Winter DC; Geoghegan J; Doherty DG; O'Farrelly C
Eur J Immunol; 2009 Jul; 39(7):1893-901. PubMed ID: 19585513
[TBL] [Abstract][Full Text] [Related]
16. Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases.
Molling JW; Moreno M; de Groot J; van der Vliet HJ; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
Immunol Lett; 2008 Jun; 118(1):36-43. PubMed ID: 18405982
[TBL] [Abstract][Full Text] [Related]
17. Natural killer T cells and haemopoiesis.
Karadimitris A; Patterson S; Spanoudakis E
Br J Haematol; 2006 Aug; 134(3):263-72. PubMed ID: 16848769
[TBL] [Abstract][Full Text] [Related]
18. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
Fujii S
Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
[TBL] [Abstract][Full Text] [Related]
19. Clinical applications of natural killer T cell-based immunotherapy for cancer.
Motohashi S; Nakayama T
Cancer Sci; 2008 Apr; 99(4):638-45. PubMed ID: 18294290
[TBL] [Abstract][Full Text] [Related]
20. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation.
Gigli G; Caielli S; Cutuli D; Falcone M
Immunology; 2007 Nov; 122(3):409-17. PubMed ID: 17617156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]